BioSpace News Archive

A team consisting of Keck Graduate Institute (KGI) Professor Jim Sterling, Western University Professor Lyna Luo, and postdoctoral scientists Wenjuan Jiang and Wesley Botello-Smith have discovered important physical mechanisms that cell surfaces utilize to provide innate immunity.

Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Barclays Global Healthcare Conference,

Blueprint Medicines Corporation announced that, effective on March 1, 2021, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 15,474 shares of its common stock and an aggregate of 7,736 restricted stock units to nine new employees under Blueprint Medicines’ 2020 Inducement Plan.

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted two new employees restricted stock units to acquire 57,000 shares of the company’s common stock.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (“Regulus”), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Global Life Sciences Conference

Healthpeak Properties, Inc. (NYSE: PEAK) announced today that Tom Herzog, its Chief Executive Officer, is scheduled to present at the Barclays 2021 Global Healthcare Conference.

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that on March 4, 2021

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Company’s management team will participate in a fireside chat at the Roth Conference being held from March 15-17, 2021

Due to its large size a biopharmaceutical generally exhibits complex three-dimensional higher-order structures (HOS) which are important factors in the protein’s biological function and activity – and thus essential for the therapeutic’s in-vivo efficiency and safety.

MedinCell (Paris:MEDCL): No safety concern is anticipated that would prevent health authorities from assessing the use of Ivermectin against Covid-19 as a new indication The expert review written by a prominent toxicologist is an assessment of ivermectin medical safety profile It is based on an extensive analysis of over 350 articles plus clearly identified and accessible web sources